ArticleNeuroscience letters2023

The FDA-approved compound, pramipexole and the clinical-stage investigational drug, dexpramipexole, reverse chronic allodynia from sciatic nerve damage in mice, and alter IL-1β and IL-10 expression from immune cell culture.

J E Sanchez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.